IPM Take
The obesity drug revolution is not just a pharmaceutical story anymore. It is becoming a rationing story. WHO’s new expert group signals that the central question is no longer whether GLP-1 therapies work, but how countries should allocate them when demand is huge, prices are high, supply is limited and health systems are unevenly prepared. Without deliberate policy, the future of obesity care could become brutally simple: private access for the wealthy, waiting lists for everyone else, and unsafe alternatives for those desperate enough to bypass the system.
Executive Summary
The World Health Organization has launched a call for experts to support the development of implementation guidance for the use of GLP-1 therapies in obesity care. The guidance will support WHO’s Living Guideline on GLP-1 therapies for adults with obesity and will focus on expected health benefit-based allocation, risk stratification, implementation pathways, affordability, equity, health-system readiness and evolving market dynamics.
This marks an important shift. WHO has already conditionally recommended GLP-1 therapies for adults with obesity, excluding pregnant women, as part of long-term, multimodal obesity care. But the agency has also warned that medicines alone will not solve the obesity crisis and that access could worsen health disparities without deliberate policy. WHO has projected that even with rapid production expansion, GLP-1 therapies may reach fewer than 10% of people who could benefit by 2030.
The new expert group is expected to be established in July 2026, with final implementation guidance planned for February 2027. Its work could shape how governments, payers and health systems prioritise GLP-1 access in a world where obesity is rising faster than health-system capacity.
Why it matters
- Policymakers: GLP-1 access will require explicit prioritisation rules, not political wishful thinking. Countries will need to decide whether treatment is prioritised by BMI, cardiometabolic risk, comorbidities, expected benefit, equity criteria or affordability.
- Public authorities: Implementation guidance could influence national obesity programmes, primary care pathways, procurement strategies, prescribing rules and public-sector coverage decisions.
- HTA bodies: Future assessments will need to move beyond average weight loss and examine expected health benefit across risk groups, long-term outcomes, discontinuation, budget impact and comparison with existing prevention and treatment models.
- Payers: The affordability question is unavoidable. Broad coverage could overwhelm budgets, while narrow coverage could deepen inequity and push patients toward unsafe private or grey-market routes.
- Clinicians: Demand for GLP-1 therapies is likely to keep rising. Clinicians will need clear criteria for patient selection, counselling, monitoring, continuation and integration with behavioural and chronic care support.
- Industry / innovation partners: WHO’s focus on affordability, market dynamics and implementation could increase pressure for tiered pricing, pooled procurement, voluntary licensing and stronger supply commitments.
- Patients / advocates: Allocation frameworks must not become a polite way to deny care. Patients need transparent rules, fair access and protection from stigma, unsafe products and purely wealth-based treatment pathways.
The global obesity drug debate is shifting from efficacy to eligibility.
For the past three years, the conversation has been dominated by clinical results: double-digit weight loss, cardiovascular benefits, expanding indications and unprecedented patient demand. But WHO’s latest move suggests that the next phase will be defined by a different question entirely: when millions of people qualify for treatment and only a fraction can realistically receive it, who goes first?
On 1 June 2026, WHO announced that it is establishing an expert group to support implementation guidance for GLP-1 therapies in obesity care. This is not another abstract technical exercise. It is the beginning of a global argument over access, allocation and fairness.
GLP-1 therapies have already changed the treatment landscape for obesity, diabetes and cardiometabolic risk. Semaglutide, tirzepatide and other incretin-based medicines have shifted expectations about what pharmacological obesity treatment can achieve. Newer candidates are pushing the field even further. But the world is now facing a harder question: what happens when a medicine is clinically powerful, publicly desired, commercially expensive and impossible to provide to everyone at once?
WHO’s answer appears to be prioritisation.
The new expert group will advise on expected health benefit-based allocation of GLP-1 therapies. That means identifying which groups are most likely to benefit, using risk stratification, prognostic tools, health outcome modelling and affordability analysis. The guidance will consider equity, feasibility, health-system readiness, implementation pathways, budget impact, pricing scenarios and changing market conditions.
In plain language: WHO is preparing countries for the politics of scarcity.
That is necessary because obesity is no longer a marginal public health issue. WHO estimates that in 2022, 2.5 billion adults were overweight, including more than 890 million adults living with obesity. In 2022, 43% of adults worldwide were overweight and 16% were living with obesity. The burden is also rising among children and adolescents, while low- and middle-income countries increasingly face the double challenge of undernutrition and obesity.
At the same time, WHO has warned that GLP-1 therapies may reach fewer than 10% of those who could benefit by 2030, even with rapid expansion in production. That figure should terrify policymakers. It means the issue is not only approval. It is not only clinical evidence. It is not only prescribing. It is the basic mismatch between global need and global access.
This is where the obesity drug revolution becomes a governance test.
Without clear rules, GLP-1 access risks being determined by wealth, geography, private insurance, supply chains and social media pressure. High-income patients may access treatment privately. Public systems may restrict coverage to narrow groups. Lower-income countries may be left waiting. Meanwhile, demand could fuel falsified products, unregulated online sales and unsafe prescribing outside structured care.
WHO has already warned that global demand for GLP-1 therapies has contributed to falsified and substandard products, threatening patient safety and trust. That warning matters because scarcity does not simply limit access. It creates markets for shortcuts.
The new guidance could therefore become one of the most important obesity policy documents of the next year.
If done well, it could help countries prioritise treatment for people at highest cardiometabolic risk, including those with obesity-related complications, type 2 diabetes, cardiovascular disease, kidney disease or other serious comorbidities. It could support phased implementation, fair procurement, better prescribing pathways and health-system planning. It could also help governments avoid a situation where GLP-1 therapies are introduced as isolated products rather than as part of lifelong obesity care.
But there is a danger.
Risk-based allocation can become technocratic cover for rationing if equity is not built in from the start. People with the greatest health need are often the same people with the least access to diagnosis, specialist care, stable follow-up and digital health systems. If allocation frameworks rely too heavily on data-rich pathways, they may favour patients already visible to the system and exclude those most affected by structural barriers.
That would reproduce the very inequities WHO says it wants to prevent.
The agency’s own 2025 guideline emphasised that medication alone will not reverse the obesity crisis. It called for healthier environments, targeted screening and structured early interventions, and lifelong person-centred care. That point is politically important. GLP-1 therapies may become essential tools, but they cannot substitute for food policy, prevention, primary care, physical activity environments, mental health support and action against stigma.
For IPM, the signal is clear.
Obesity medicines are moving from breakthrough science into the machinery of health policy. The next battle will not only be in clinical trials. It will be in ministries of health, procurement agencies, payer committees, pharmacies, primary care clinics and global access negotiations.
The question is no longer whether GLP-1 therapies can change obesity care.
The question is whether the world can prevent them from becoming another example of medical innovation arriving first for those who can pay, and last for those who carry the greatest burden.
